A

Adverum Biotechnologies
D

ADVM

4.33000
USD
0.05
(1.17%)
مغلق
حجم التداول
1,856
الربح لكل سهم
-6
العائد الربحي
-
P/E
-1
حجم السوق
90,074,665
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    B
    BLUE
    0.05000
    (0.60%)
    8.35000 USD
    B
    BMRN
    0.260
    (0.42%)
    61.570 USD
    C
    CRSP
    0.260
    (0.65%)
    40.520 USD
    E
    EDIT
    -0.03000
    (-2.40%)
    1.22000 USD
    GILD
    GILD
    0.150
    (0.16%)
    91.790 USD
    MRNA
    MRNA
    0.310
    (0.92%)
    34.050 USD
    REGN
    REGN
    -11.37
    (-1.64%)
    681.49 USD
    S
    SGMO
    -0.00500
    (-0.45%)
    1.10000 USD
    V
    VYGR
    0.01000
    (0.20%)
    5.06000 USD
    المزيد
الأخبار
المقالات

العنوان: Adverum Biotechnologies

القطاع: Healthcare
الصناعة: Biotechnology
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.